Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1

Proceedings of the National Academy of Sciences of the United States of America
Junpeng QiChristoph Rader

Abstract

T cell-engaging bispecific antibodies (biAbs) present a promising strategy for cancer immunotherapy, and numerous bispecific formats have been developed for retargeting cytolytic T cells toward tumor cells. To explore the therapeutic utility of T cell-engaging biAbs targeting the receptor tyrosine kinase ROR1, which is expressed by tumor cells of various hematologic and solid malignancies, we used a bispecific ROR1 × CD3 scFv-Fc format based on a heterodimeric and aglycosylated Fc domain designed for extended circulatory t1/2 and diminished systemic T cell activation. A diverse panel of ROR1-targeting scFv derived from immune and naïve rabbit antibody repertoires was compared in this bispecific format for target-dependent T cell recruitment and activation. An ROR1-targeting scFv with a membrane-proximal epitope, R11, revealed potent and selective antitumor activity in vitro, in vivo, and ex vivo and emerged as a prime candidate for further preclinical and clinical studies. To elucidate the precise location and engagement of this membrane-proximal epitope, which is conserved between human and mouse ROR1, the 3D structure of scFv R11 in complex with the kringle domain of ROR1 was determined by X-ray crystallography at 1.6-Å resol...Continue Reading

References

Jul 28, 1995·International Journal of Cancer. Journal International Du Cancer·Z ZhuP Carter
Jul 14, 1998·Nature Biotechnology·A M MerchantP Carter
May 23, 2001·Protein Science : a Publication of the Protein Society·Q YeZ Jia
Sep 16, 2003·Journal of Molecular Biology·Christoph RaderCarlos F Barbas
May 12, 2004·Proceedings of the National Academy of Sciences of the United States of America·Lars Kjer-NielsenJamie Rossjohn
Jul 13, 2004·Science·Joseph N Blattman, Philip D Greenberg
Nov 10, 2004·Proceedings of the National Academy of Sciences of the United States of America·Kelly L ArnettDon C Wiley
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Paul Emsley, Kevin Cowtan
Feb 8, 2005·The Journal of Biological Chemistry·HaJeung ParkJeffrey C Boyington
Aug 8, 2007·Journal of Molecular Biology·Evgeny Krissinel, Kim Henrick
Dec 21, 2007·Acta Crystallographica. Section D, Biological Crystallography·Fei LongGarib N Murshudov
Jan 29, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sivasubramanian BaskarChristoph Rader
Feb 22, 2008·Proceedings of the National Academy of Sciences of the United States of America·Tetsuya FukudaThomas J Kipps
Jun 12, 2008·International Journal of Cancer. Journal International Du Cancer·Amir H DaneshmaneshHodjattallah Rabbani
Jan 9, 2010·Acta Crystallographica. Section D, Biological Crystallography·Vincent B ChenDavid C Richardson
Feb 4, 2010·Acta Crystallographica. Section D, Biological Crystallography·Paul D AdamsPeter H Zwart
Apr 13, 2010·Acta Crystallographica. Section D, Biological Crystallography·Marc Schiltz, Gérard Bricogne
Jul 3, 2010·Hematological Oncology·Gábor BarnaAndrás Matolcsy
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·T Geoff G BattyeAndrew G W Leslie
Mar 20, 2012·Molecular Biotechnology·Dmitrij HristodorovLars Linden
Apr 26, 2012·MAbs·Sivasubramanian BaskarChristoph Rader
Apr 27, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael HudecekStanley R Riddell
Apr 30, 2013·Current Opinion in Chemical Biology·Stanley R Frankel, Patrick A Baeuerle
Jul 30, 2014·Seminars in Cancer Biology·Mohammad Hojjat-FarsangiHåkan Mellstedt
Oct 31, 2014·Cancer Immunology Research·Carolina BergerStanley R Riddell
Jan 7, 2015·Annual Review of Pharmacology and Toxicology·Andreas Plückthun
May 2, 2015·Trends in Biotechnology·Katja ŠkrlecAleš Berlec
Oct 31, 2015·MAbs·Felix UnverdorbenRoland E Kontermann
Feb 7, 2016·The Journal of Biological Chemistry·Mohosin SarkarThomas Kodadek
Jun 7, 2016·Nature Reviews. Immunology·Maike de la RocheGillian M Griffiths
Jul 23, 2016·The Journal of Biological Chemistry·Even WalsengChristoph Rader
Aug 24, 2016·Nature Reviews. Cancer·Andrew D FesnakBruce L Levine
Nov 18, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ashwini BalakrishnanStanley R Riddell
Nov 20, 2016·Current Opinion in Structural Biology·Doreen KönningHarald Kolmar
Jan 11, 2017·MAbs·Ulrich Brinkmann, Roland E Kontermann
Mar 2, 2017·The New England Journal of Medicine·Hagop KantarjianMax S Topp

❮ Previous
Next ❯

Citations

Apr 3, 2019·Expert Opinion on Therapeutic Targets·Amin KamraniMehdi Yousefi
Dec 7, 2018·Journal of Immunotherapy·Gennaro RiccioClaudia De Lorenzo
Sep 6, 2019·International Journal of Molecular Sciences·Tom HoflandSanne H Tonino
Dec 9, 2020·Organic & Biomolecular Chemistry·Mark Agostino, Sebastian Öther-Gee Pohl
Jan 16, 2021·Cells·Kerstin MenckAnnalen Bleckmann
Jan 16, 2021·Advanced Healthcare Materials·Anthony BrouillardAshish A Kulkarni
Jan 21, 2021·Cancers·Jim MiddelburgThorbald van Hall
Dec 17, 2019·Current Opinion in Biotechnology·Christoph Rader
Feb 17, 2020·Antibody Therapeutics·Siwei NieJijie Gu
Aug 24, 2021·Blood Advances·Eileen Y HuNatarajan Muthusamy
Jul 8, 2021·Scientific Reports·Nadine AschmoneitRoland E Kontermann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Repertoire Diversity

Antibody repertoire diversity and its role during natural infection is a prerequisite for molecular and structural elucidation of functionally protective immunity. Discover the latest insights into antibody diversity here.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.